Results 11 to 20 of about 78,382 (206)
Overcoming resistance to BRAF inhibitors [PDF]
Annals of Translational Medicine, 2017 The discovery of activating mutations in the serine/threonine (S/T) kinase BRAF followed by a wave of follow-up research manifested that the MAPK-pathway plays a critical role in melanoma initiation and progression. BRAF and MEK inhibitors produce an unparalleled response rate in melanoma, but it is now clear that most responses are transient, and ...
Arozarena, Imanol, Wellbrock, Claudia
openaire +2 more sources
BRAF inhibitors in clinical oncology [PDF]
F1000Prime Reports, 2013 Activating mutations of the BRAF oncogene are present in approximately 5-10% of all human malignancies and lead to constitutive activation of the mitogen activated protein kinase (MAPK) pathway. The introduction of BRAF inhibitors has greatly improved the short term prospects of some patients with these tumors, but the tumors tend to become resistant ...
Morris, Van, Kopetz, Scott
openaire +2 more sources
BRAF Inhibitor Resistance Confers Increased Sensitivity to Mitotic Inhibitors. [PDF]
Front Oncol, 2022 Single agent and combination therapy with BRAF V600E/K and MEK inhibitors have remarkable efficacy against melanoma tumors with activating BRAF mutations, but in most cases BRAF inhibitor (BRAFi) resistance eventually develops.
Misek SA +7 more
europepmc +4 more sources
Cancer Biology & Therapy, 2023 The treatment of BRAFV600E mutant melanoma has been revolutionized by BRAF inhibitors. Furthermore, the BRAF/MEK combination has shown further improvement in clinical outcomes in advanced and in adjuvant melanoma patients.
Sandro Anchisi +8 more
doaj +1 more source
Targeting Oncogenic BRAF: Past, Present, and Future. [PDF]
, 2019 Identifying recurrent somatic genetic alterations of, and dependency on, the kinase BRAF has enabled a "precision medicine" paradigm to diagnose and treat BRAF-driven tumors.
Bivona, Trever G +2 more
core +1 more source
Multiple organ infarction caused by aortic thrombus in a lung cancer patient with the BRAF mutation
Respiratory Medicine Case Reports, 2022 A 72-year-old male patient with advanced lung adenocarcinoma harboring a BRAF mutation had received treatment with a BRAF inhibitor and a MEK inhibitor. Treatment was ceased after 40 days because of disease progression.
Hirofumi Watanabe +10 more
doaj +1 more source
Frontiers in Oncology, 2019 BRAF inhibitor therapy may provide profound initial tumor regression in metastatic melanoma with BRAF V600 mutations, but treatment resistance often leads to disease progression.
Stephen A. Luebker, Scott A. Koepsell
doaj +1 more source
Frontiers in Immunology, 2023 Anaplastic thyroid carcinoma, BRAF non-V600, NRAS, combination immunotherapy and targeted therapy, case report. Anaplastic thyroid carcinoma (ATC) is a rare type of thyroid cancer with a mortality rate near 100%. BRAF V600 and NRAS mutations are the most
Lin Gui +6 more
doaj +1 more source
Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients. [PDF]
, 2017 BackgroundMetastatic melanoma is an aggressive form of skin cancer with a high mortality rate and the fastest growing global incidence rate of all malignancies.
Ahuja, Amit +4 more
core +2 more sources
ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma
Molecular Systems Biology, 2014 Treatment of BRAF mutant melanomas with specific BRAF inhibitors leads to tumor remission. However, most patients eventually relapse due to drug resistance.
Marjon A Smit +9 more
doaj +1 more source